NovoCure

Treatment of Brain Tumors Using Electric Fields

Health Tech & Life Sciences
Public on NASDAQ on Oct, 2015<br>
Follow

Company Overview

Snapshot

Founded in April 1999 by Prof. Yoram Palti, NovoCure is a public oncology company with over 1,000 employees. The company has raised a total of $742 million across five funding rounds. In May 2024, NovoCure secured new debt financing.

Business overview

NovoCure is a commercial-stage oncology company focused on developing Tumor Treating Fields (TTFields) therapy for solid tumor cancers. This proprietary technology utilizes low-intensity, intermediate-frequency alternating electric fields to disrupt cell division. The therapy is delivered via noninvasive transducer arrays and a portable electric field generator, designed for continuous wear. NovoCure serves the healthcare and life sciences sectors, targeting patients and providers with its medical devices and treatments.

Strategic signal

In September 2024, NovoCure announced it would present real-world data at ESMO 2024, demonstrating improved survival outcomes for newly diagnosed glioblastoma patients with increased use of its Tumor Treating Fields (TTFields) therapy. This highlights the company's ongoing commitment to validating its core technology through clinical evidence and expanding its application, signaling potential for broader adoption and impact in oncology treatment.

Log in to access full profile ›

Company Intelligence Q&A

What is NovoCure's primary therapeutic focus?
NovoCure develops Tumor Treating Fields (TTFields) therapy for the treatment of solid tumor cancers, utilizing low-intensity, intermediate-frequency alternating electric fields to disrupt cell division.
When did NovoCure go public?
NovoCure became a public company on NASDAQ in October 2015.
What was a significant recent financial event for NovoCure?
In May 2024, NovoCure secured new multi-tranche non-dilutive debt financing from Pharmakon Advisors, totaling $400 million.
What recent leadership change occurred at NovoCure?
In September 2024, NovoCure announced that CEO Asaf Danziger would retire, with CFO Ashley Cordova named as his successor.
Has NovoCure received any recent regulatory approvals for its products?
In September 2025, NovoCure's Optune Lua device received approval in Japan for the treatment of unresectable advanced/recurrent non-small cell lung cancer (NSCLC).
Log in to access full profile ›

External links